Although NKILA does not directly regulate canonical TGFβ-Smad signaling, its inhibition of NF-κB signaling may interact with or counterbalance TGFβ-induced EMT and inflammatory responses, reflecting a broader antagonism to tumor-promoting signaling cascades [62]. The gene discussed is NFKB1; the disease is neoplasm.